Fintel reports that on April 30, 2024, JP Morgan initiated coverage of Immunome (NasdaqCM:IMNM) with a Overweight recommendation.
Analyst Price Forecast Suggests 160.78% Upside
As of April 17, 2024, the average one-year price target for Immunome is 36.04. The forecasts range from a low of 33.33 to a high of $39.90. The average price target represents an increase of 160.78% from its latest reported closing price of 13.82.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Immunome is 291MM, an increase of 1,973.76%. The projected annual non-GAAP EPS is 4.30.
What is the Fund Sentiment?
There are 93 funds or institutions reporting positions in Immunome. This is an increase of 30 owner(s) or 47.62% in the last quarter. Average portfolio weight of all funds dedicated to IMNM is 0.17%, an increase of 167.69%. Total shares owned by institutions increased in the last three months by 776.04% to 22,478K shares. 
The put/call ratio of IMNM is 0.18, indicating a bullish outlook.
What are Other Shareholders Doing?
EcoR1 Capital holds 3,879K shares representing 6.50% ownership of the company.
Redmile Group holds 3,879K shares representing 6.50% ownership of the company.
Janus Henderson Group holds 1,391K shares representing 2.33% ownership of the company.
Avidity Partners Management holds 1,333K shares representing 2.23% ownership of the company.
FDGRX - Fidelity Growth Company Fund holds 1,244K shares representing 2.08% ownership of the company.
Immunome Background Information
(This description is provided by the company.)
Immunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics that are designed to change the way diseases are treated. The company's initial focus is on developing therapeutics to treat oncology and infectious diseases, including COVID-19. Immunome's proprietary discovery engine identifies novel therapeutic antibodies and their targets by leveraging the highly educated components of the immune system, memory B cells, from patients whose bodies have learned to fight off their disease.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
